Diagnovus announced the launch of the Engauge GI–Barrett’s Esophagus, the first available genomic assay to aid in predicting the risk of progression to high-grade dysplasia or esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus.
Engauge GI–Barrett’s Esophagus is a proprietary gene expression assay that uses RT-PCR to determine the methylation profile of an 8-gene panel. Methylation is a signaling tool used by cells that is common in cancer development and may play a role in the carcinogenic process.
The assay uses routine biopsy material taken during endoscopic surveillance and can be performed in a highly reproducible and accurate manner using formalin-fixed paraffin embedded diagnostic biopsy tissue.
For more information call (855) 642-8438 or visit Diagnovus.com.